What Alector’s Phase III miss may say about FTD biology: Clinical Report

Clinical updates were numerous this week as this year’s ESMO meeting took place over the weekend, but the largest stock moves came from smaller biotechs with programs in neurological disorders.

Shares of Alector Inc. (NASDAQ:ALEC) fell 50% Wednesday, bringing its market cap down to about $162 million, after its SORT1-targeting mAb latozinemab failed to slow disease progression in frontotemporal dementia patients with GRN mutations (FTD-GRN) in the INFRONT-3 Phase III trial...